Operationalizing GxP-level quality for the translational reliability of organoids
A persistent gap remains between early-stage promise and real clinical outcomes in oncology.
Patient-derived organoids offer a more predictive, human-relevant approach by replicating the complexity of human tumors. But their impact depends on more than biology alone.
To become truly decision-grade, organoids must be built on two critical pillars: biological fidelity and operational rigor, ensuring results are not only relevant, but reproducible and scalable.
In this article, SEAHEE KIM, Director of Organoids Technology at Samsung Biologics, explores how GxP-aligned quality systems can help unlock the full translational potential of organoid platforms.
Read the full article to learn how organoids are evolving into standardized tools for precision oncology.
A persistent gap remains between early-stage promise and real clinical outcomes in oncology.
Patient-derived organoids offer a more predictive, human-relevant approach by replicating the complexity of human tumors. But their impact depends on more than biology alone.
To become truly decision-grade, organoids must be built on two critical pillars: biological fidelity and operational rigor, ensuring results are not only relevant, but reproducible and scalable.
In this article, SEAHEE KIM, Director of Organoids Technology at Samsung Biologics, explores how GxP-aligned quality systems can help unlock the full translational potential of organoid platforms.
Read the full article to learn how organoids are evolving into standardized tools for precision oncology.
Share article
Related Content